Practice

Study Highlights Role of Health Plan Type in Biosimilar Adoption

January 16th 2024

By Skylar Jeremias

A study examining biosimilar uptake patterns within different health insurance plans found that low-flexibility plans, such as health maintenance organizations and exclusive provider organizations, were more likely to initiate biosimilar therapies than more flexible plans.

IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe

January 10th 2024

By Skylar Jeremias

Article

IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.

Examining Attitudes in German, Swiss Pharmacists on Biosimilar Dispensing Pre- and Post Pandemic

January 9th 2024

By Cameron Santoro

Article

A recent study found that the COVID-19 pandemic had little impact on the knowledge and attitudes of German and Swiss pharmacists regarding biologics and biosimilars between 2020 and 2022.

Quiz: The Basics of Biosimilars

January 8th 2024

By The Center for Biosimilars Staff

Article

Intro to Biosimilars is now in session! Test yourself on how well you know these biosimilar basics.

SABCS Posters Evaluate Real-World Outcomes Associated With Ogivri

December 14th 2023

By Skylar Jeremias

Article

Two Taiwanese posters presented at the San Antonio Breast Cancer Symposium (SABCS) 2023 annual meeting evaluated the real-world implications of using trastuzumab biosimilars, particularly Ogivri (trastuzumab-dkst) in patients with HER2-postive breast cancer.

Factors Physicians Should Consider When Selecting an Adalimumab Biosimilar

December 9th 2023

By Deana Ferreri, PhD

Article

A review article discussed the characteristics of the available adalimumab biosimilars to help clinicians navigate the various treatment options with their patients.

Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models

December 7th 2023

By Laura Joszt

Article

A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.

Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions

December 2nd 2023

By Deana Ferreri, PhD

Article

A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.

IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity

November 29th 2023

By Skylar Jeremias

Article

A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.

HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain

November 28th 2023

By Skylar Jeremias

Article

Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.